Browsing Tag
Hemab Therapeutics
2 posts
Sutacimig Phase 3 path puts Hemab’s $457.5m post-IPO cash base to work
Sutacimig gets an FDA-backed Phase 3 path as Hemab deploys its $457.5m post-IPO cash base. See what the pivotal trial means for growth.
Hemab Therapeutics raises $135m for prophylactic treatments for bleeding and thrombotic disorders
Hemab Therapeutics, a clinical-stage biotechnology company, has raised $135 million in a Series B financing round for advancing…